Biotech vet Rastetter takes helm at Fate; BMS, China's Simcere add cardio program to pact;

 @FierceBiotech: In another rare disease push, GSK is teaming with University of Dundee researchers to find Huntingdon's treatment. Report | Follow @FierceBiotech

 @JohnCFierce: Strong arguments from Harvard's Carpenter on making FDA independent. Not gonna happen, but it's an intelligent piece. Article | Follow @JohnCFierce

> San Diego-based Fate Therapeutics has tapped biotech vet Bill Rastetter as its new CEO. Rastetter, a partner at Venrock, is chairman of Illumina, Neurocrine and Receptos. Fate release

> China's Simcere has expanded its collaboration deal with Bristol-Myers Squibb to include a second program on a cardiovascular treatment. No terms were released. Simcere release

> Onyx has joined the Multiple Myeloma Foundation's pre-competitive consortium on myeloma, which aims at the advancement of new, targeted myeloma treatments. Release

> Profectus BioSciences has nailed a $5.4 million NIH grant to develop a new vaccine for the closely linked Nipah and Hendra viruses. Story

> The Atlantic Research Group, a contract research firm, is moving to Charlottesville, VA next spring. Story

Pharma News

 @FiercePharma: Packaging veteran urges including patient in drug pedigree chain. Story | Follow@FiercePharma

> AZ, GSK ask carmakers for directions amid pharma breakdown. News

> Report: GSK closing in on deal with Boston PE group for OTC assets. Story

> Enbrel beats rivals in rheumatologist survey. Survey

FierceDrugDelivery

> Immunomedics promotes 2 cancer treatments to later-stage trials. News

> India university creates low-cost insulin pump: commercial partners wanted. Report

> Nanoparticles carting steroids to retina delay macular degeneration. Item

> Silk may be basis for smoothest microneedle system yet. Article

FierceBiomarkers

> Biomarkers provide route to personalized medicine. Piece

> BNP may serve as prognostic biomarker in valve disease. News

> Next-gen sequencing pinpoints breast cancer biomarkers. Story

> Diabetes collaboration to identify biomarkers. Item

FierceMedicalDevices

> Infrascan gets FDA's OK for hematoma detector. News

> Ventana, ACD ink co-promotion deal. Item

> Final Synthes exec sentenced in Norian case. Report

> Baxter enters agreement to buy Synovis for $325M. Article

And Finally... An epidemic of obesity and diabetes has triggered a sharp spike in the number of incidents of nonalcoholic steatohepatitis (NASH)--when fat builds up in the liver. Release

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.